Elicio Therapeutics’ Promising Early Results in Cancer Vaccine Trial
Company Announcements

Elicio Therapeutics’ Promising Early Results in Cancer Vaccine Trial

Elicio Therapeutics (ELTX) just unveiled an update.

Elicio Therapeutics, Inc. has shared encouraging preliminary results from the AMPLIFY-7P Phase 1a study of their experimental cancer vaccine, ELI-002 7P, which targets mKRAS-driven solid tumors. The data, as of May 2024, reveal that patients receiving a higher dose of the vaccine have not yet reached the median disease-free survival endpoint, indicating potential effectiveness. Those with higher T cell responses to the vaccine also showed no signs of disease progression, highlighting the promise of ELI-002 7P in treating such challenging cancers.

See more insights into ELTX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyElicio Therapeutics reports Q3 EPS ($1.39), consensus (73c)
TheFlyElicio Therapeutics files to sell 3.44M shares of common stock for holders
TheFlyElicio Therapeutics presents updated preliminary results from AMPLIFY-7P
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App